 Global Osteoporosis Biosimilars Market Growth 2026-2032
The global Osteoporosis Biosimilars market size is predicted to grow from US$ 1890 million in 2025 to US$ 2415 million in 2032; it is expected to grow at a CAGR of 3.6% from 2026 to 2032. Osteopor... もっと見る
SummaryThe global Osteoporosis Biosimilars market size is predicted to grow from US$ 1890 million in 2025 to US$ 2415 million in 2032; it is expected to grow at a CAGR of 3.6% from 2026 to 2032.Osteoporosis biosimilars are a class of follow-up biologic products that are equivalent to approved osteoporosis biologic drugs in quality, safety and efficacy. They go through a rigorous regulatory process and demonstrate no significant differences in key properties from the original drug, providing patients with additional treatment options and potentially increasing treatment accessibility due to their lower cost. United States market for Osteoporosis Biosimilars is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032. China market for Osteoporosis Biosimilars is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032. Europe market for Osteoporosis Biosimilars is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032. Global key Osteoporosis Biosimilars players cover Biosidus SA, Cadila Pharmaceuticals, Gedeon Richter Australia Pty Ltd, Mochida Pharmaceutical Co., Ltd, STADA Arzneimittel AG, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025. LP Information, Inc. (LPI) ' newest research report, the “Osteoporosis Biosimilars Industry Forecast” looks at past sales and reviews total world Osteoporosis Biosimilars sales in 2025, providing a comprehensive analysis by region and market sector of projected Osteoporosis Biosimilars sales for 2026 through 2032. With Osteoporosis Biosimilars sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Osteoporosis Biosimilars industry. This Insight Report provides a comprehensive analysis of the global Osteoporosis Biosimilars landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Osteoporosis Biosimilars portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Osteoporosis Biosimilars market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Osteoporosis Biosimilars and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Osteoporosis Biosimilars. This report presents a comprehensive overview, market shares, and growth opportunities of Osteoporosis Biosimilars market by product type, application, key manufacturers and key regions and countries. Segmentation by Type: 250μg/mL 60 mg/mL 70 mg/mL Segmentation by Application: Hospital Clinic Others This report also splits the market by region: Americas United States Canada Mexico Brazil APAC China Japan Korea Southeast Asia India Australia Europe Germany France UK Italy Russia Middle East & Africa Egypt South Africa Israel Turkey GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration. Biosidus SA Cadila Pharmaceuticals Gedeon Richter Australia Pty Ltd Mochida Pharmaceutical Co., Ltd STADA Arzneimittel AG Alvogen, Inc Theramex Ireland Ltd Intas Pharmaceuticals Ltd Sun Pharma ANZ Pty Ltd Strides Pharma Apotex Corp Teva Pharmaceuticals, Inc Novartis AG Cipla Ltd CrownBio Science (Jilin) Co., Ltd LianKang Biotechnology Group Shanghai United Cell Bioengineering Co., Ltd Shenzhen Salubris Pharmaceuticals Co., Ltd Shandong Boyan Biotechnology Co., Ltd Mabwell (Shanghai) Biotechnology Qilu Pharmaceutical Co., Ltd Key Questions Addressed in this Report What is the 10-year outlook for the global Osteoporosis Biosimilars market? What factors are driving Osteoporosis Biosimilars market growth, globally and by region? Which technologies are poised for the fastest growth by market and region? How do Osteoporosis Biosimilars market opportunities vary by end market size? How does Osteoporosis Biosimilars break out by Type, by Application? Table of Contents1 Scope of the Report1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Osteoporosis Biosimilars Annual Sales 2021-2032 2.1.2 World Current & Future Analysis for Osteoporosis Biosimilars by Geographic Region, 2021, 2025 & 2032 2.1.3 World Current & Future Analysis for Osteoporosis Biosimilars by Country/Region, 2021, 2025 & 2032 2.2 Osteoporosis Biosimilars Segment by Type 2.2.1 250μg/mL 2.2.2 60 mg/mL 2.2.3 70 mg/mL 2.2.4 Osteoporosis Biosimilars Sales by Type 2.2.4.1 Global Osteoporosis Biosimilars Sales Market Share by Type (2021-2026) 2.2.4.2 Global Osteoporosis Biosimilars Revenue and Market Share by Type (2021-2026) 2.2.4.3 Global Osteoporosis Biosimilars Sale Price by Type (2021-2026) 2.3 Osteoporosis Biosimilars Segment by Application 2.3.1 Hospital 2.3.2 Clinic 2.3.3 Others 2.3.4 Osteoporosis Biosimilars Sales by Application 2.3.4.1 Global Osteoporosis Biosimilars Sale Market Share by Application (2021-2026) 2.3.4.2 Global Osteoporosis Biosimilars Revenue and Market Share by Application (2021-2026) 2.3.4.3 Global Osteoporosis Biosimilars Sale Price by Application (2021-2026) 3 Global by Company 3.1 Global Osteoporosis Biosimilars Breakdown Data by Company 3.1.1 Global Osteoporosis Biosimilars Annual Sales by Company (2021-2026) 3.1.2 Global Osteoporosis Biosimilars Sales Market Share by Company (2021-2026) 3.2 Global Osteoporosis Biosimilars Annual Revenue by Company (2021-2026) 3.2.1 Global Osteoporosis Biosimilars Revenue by Company (2021-2026) 3.2.2 Global Osteoporosis Biosimilars Revenue Market Share by Company (2021-2026) 3.3 Global Osteoporosis Biosimilars Sale Price by Company 3.4 Key Manufacturers Osteoporosis Biosimilars Producing Area Distribution, Sales Area, Product Type 3.4.1 Key Manufacturers Osteoporosis Biosimilars Product Location Distribution 3.4.2 Players Osteoporosis Biosimilars Products Offered 3.5 Market Concentration Rate Analysis 3.5.1 Competition Landscape Analysis 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026) 3.6 New Products and Potential Entrants 3.7 Market M&A Activity & Strategy 4 World Historic Review for Osteoporosis Biosimilars by Geographic Region 4.1 World Historic Osteoporosis Biosimilars Market Size by Geographic Region (2021-2026) 4.1.1 Global Osteoporosis Biosimilars Annual Sales by Geographic Region (2021-2026) 4.1.2 Global Osteoporosis Biosimilars Annual Revenue by Geographic Region (2021-2026) 4.2 World Historic Osteoporosis Biosimilars Market Size by Country/Region (2021-2026) 4.2.1 Global Osteoporosis Biosimilars Annual Sales by Country/Region (2021-2026) 4.2.2 Global Osteoporosis Biosimilars Annual Revenue by Country/Region (2021-2026) 4.3 Americas Osteoporosis Biosimilars Sales Growth 4.4 APAC Osteoporosis Biosimilars Sales Growth 4.5 Europe Osteoporosis Biosimilars Sales Growth 4.6 Middle East & Africa Osteoporosis Biosimilars Sales Growth 5 Americas 5.1 Americas Osteoporosis Biosimilars Sales by Country 5.1.1 Americas Osteoporosis Biosimilars Sales by Country (2021-2026) 5.1.2 Americas Osteoporosis Biosimilars Revenue by Country (2021-2026) 5.2 Americas Osteoporosis Biosimilars Sales by Type (2021-2026) 5.3 Americas Osteoporosis Biosimilars Sales by Application (2021-2026) 5.4 United States 5.5 Canada 5.6 Mexico 5.7 Brazil 6 APAC 6.1 APAC Osteoporosis Biosimilars Sales by Region 6.1.1 APAC Osteoporosis Biosimilars Sales by Region (2021-2026) 6.1.2 APAC Osteoporosis Biosimilars Revenue by Region (2021-2026) 6.2 APAC Osteoporosis Biosimilars Sales by Type (2021-2026) 6.3 APAC Osteoporosis Biosimilars Sales by Application (2021-2026) 6.4 China 6.5 Japan 6.6 South Korea 6.7 Southeast Asia 6.8 India 6.9 Australia 6.10 China Taiwan 7 Europe 7.1 Europe Osteoporosis Biosimilars by Country 7.1.1 Europe Osteoporosis Biosimilars Sales by Country (2021-2026) 7.1.2 Europe Osteoporosis Biosimilars Revenue by Country (2021-2026) 7.2 Europe Osteoporosis Biosimilars Sales by Type (2021-2026) 7.3 Europe Osteoporosis Biosimilars Sales by Application (2021-2026) 7.4 Germany 7.5 France 7.6 UK 7.7 Italy 7.8 Russia 8 Middle East & Africa 8.1 Middle East & Africa Osteoporosis Biosimilars by Country 8.1.1 Middle East & Africa Osteoporosis Biosimilars Sales by Country (2021-2026) 8.1.2 Middle East & Africa Osteoporosis Biosimilars Revenue by Country (2021-2026) 8.2 Middle East & Africa Osteoporosis Biosimilars Sales by Type (2021-2026) 8.3 Middle East & Africa Osteoporosis Biosimilars Sales by Application (2021-2026) 8.4 Egypt 8.5 South Africa 8.6 Israel 8.7 Turkey 8.8 GCC Countries 9 Market Drivers, Challenges and Trends 9.1 Market Drivers & Growth Opportunities 9.2 Market Challenges & Risks 9.3 Industry Trends 10 Manufacturing Cost Structure Analysis 10.1 Raw Material and Suppliers 10.2 Manufacturing Cost Structure Analysis of Osteoporosis Biosimilars 10.3 Manufacturing Process Analysis of Osteoporosis Biosimilars 10.4 Industry Chain Structure of Osteoporosis Biosimilars 11 Marketing, Distributors and Customer 11.1 Sales Channel 11.1.1 Direct Channels 11.1.2 Indirect Channels 11.2 Osteoporosis Biosimilars Distributors 11.3 Osteoporosis Biosimilars Customer 12 World Forecast Review for Osteoporosis Biosimilars by Geographic Region 12.1 Global Osteoporosis Biosimilars Market Size Forecast by Region 12.1.1 Global Osteoporosis Biosimilars Forecast by Region (2027-2032) 12.1.2 Global Osteoporosis Biosimilars Annual Revenue Forecast by Region (2027-2032) 12.2 Americas Forecast by Country (2027-2032) 12.3 APAC Forecast by Region (2027-2032) 12.4 Europe Forecast by Country (2027-2032) 12.5 Middle East & Africa Forecast by Country (2027-2032) 12.6 Global Osteoporosis Biosimilars Forecast by Type (2027-2032) 12.7 Global Osteoporosis Biosimilars Forecast by Application (2027-2032) 13 Key Players Analysis 13.1 Biosidus SA 13.1.1 Biosidus SA Company Information 13.1.2 Biosidus SA Osteoporosis Biosimilars Product Portfolios and Specifications 13.1.3 Biosidus SA Osteoporosis Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026) 13.1.4 Biosidus SA Main Business Overview 13.1.5 Biosidus SA Latest Developments 13.2 Cadila Pharmaceuticals 13.2.1 Cadila Pharmaceuticals Company Information 13.2.2 Cadila Pharmaceuticals Osteoporosis Biosimilars Product Portfolios and Specifications 13.2.3 Cadila Pharmaceuticals Osteoporosis Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026) 13.2.4 Cadila Pharmaceuticals Main Business Overview 13.2.5 Cadila Pharmaceuticals Latest Developments 13.3 Gedeon Richter Australia Pty Ltd 13.3.1 Gedeon Richter Australia Pty Ltd Company Information 13.3.2 Gedeon Richter Australia Pty Ltd Osteoporosis Biosimilars Product Portfolios and Specifications 13.3.3 Gedeon Richter Australia Pty Ltd Osteoporosis Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026) 13.3.4 Gedeon Richter Australia Pty Ltd Main Business Overview 13.3.5 Gedeon Richter Australia Pty Ltd Latest Developments 13.4 Mochida Pharmaceutical Co., Ltd 13.4.1 Mochida Pharmaceutical Co., Ltd Company Information 13.4.2 Mochida Pharmaceutical Co., Ltd Osteoporosis Biosimilars Product Portfolios and Specifications 13.4.3 Mochida Pharmaceutical Co., Ltd Osteoporosis Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026) 13.4.4 Mochida Pharmaceutical Co., Ltd Main Business Overview 13.4.5 Mochida Pharmaceutical Co., Ltd Latest Developments 13.5 STADA Arzneimittel AG 13.5.1 STADA Arzneimittel AG Company Information 13.5.2 STADA Arzneimittel AG Osteoporosis Biosimilars Product Portfolios and Specifications 13.5.3 STADA Arzneimittel AG Osteoporosis Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026) 13.5.4 STADA Arzneimittel AG Main Business Overview 13.5.5 STADA Arzneimittel AG Latest Developments 13.6 Alvogen, Inc 13.6.1 Alvogen, Inc Company Information 13.6.2 Alvogen, Inc Osteoporosis Biosimilars Product Portfolios and Specifications 13.6.3 Alvogen, Inc Osteoporosis Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026) 13.6.4 Alvogen, Inc Main Business Overview 13.6.5 Alvogen, Inc Latest Developments 13.7 Theramex Ireland Ltd 13.7.1 Theramex Ireland Ltd Company Information 13.7.2 Theramex Ireland Ltd Osteoporosis Biosimilars Product Portfolios and Specifications 13.7.3 Theramex Ireland Ltd Osteoporosis Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026) 13.7.4 Theramex Ireland Ltd Main Business Overview 13.7.5 Theramex Ireland Ltd Latest Developments 13.8 Intas Pharmaceuticals Ltd 13.8.1 Intas Pharmaceuticals Ltd Company Information 13.8.2 Intas Pharmaceuticals Ltd Osteoporosis Biosimilars Product Portfolios and Specifications 13.8.3 Intas Pharmaceuticals Ltd Osteoporosis Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026) 13.8.4 Intas Pharmaceuticals Ltd Main Business Overview 13.8.5 Intas Pharmaceuticals Ltd Latest Developments 13.9 Sun Pharma ANZ Pty Ltd 13.9.1 Sun Pharma ANZ Pty Ltd Company Information 13.9.2 Sun Pharma ANZ Pty Ltd Osteoporosis Biosimilars Product Portfolios and Specifications 13.9.3 Sun Pharma ANZ Pty Ltd Osteoporosis Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026) 13.9.4 Sun Pharma ANZ Pty Ltd Main Business Overview 13.9.5 Sun Pharma ANZ Pty Ltd Latest Developments 13.10 Strides Pharma 13.10.1 Strides Pharma Company Information 13.10.2 Strides Pharma Osteoporosis Biosimilars Product Portfolios and Specifications 13.10.3 Strides Pharma Osteoporosis Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026) 13.10.4 Strides Pharma Main Business Overview 13.10.5 Strides Pharma Latest Developments 13.11 Apotex Corp 13.11.1 Apotex Corp Company Information 13.11.2 Apotex Corp Osteoporosis Biosimilars Product Portfolios and Specifications 13.11.3 Apotex Corp Osteoporosis Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026) 13.11.4 Apotex Corp Main Business Overview 13.11.5 Apotex Corp Latest Developments 13.12 Teva Pharmaceuticals, Inc 13.12.1 Teva Pharmaceuticals, Inc Company Information 13.12.2 Teva Pharmaceuticals, Inc Osteoporosis Biosimilars Product Portfolios and Specifications 13.12.3 Teva Pharmaceuticals, Inc Osteoporosis Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026) 13.12.4 Teva Pharmaceuticals, Inc Main Business Overview 13.12.5 Teva Pharmaceuticals, Inc Latest Developments 13.13 Novartis AG 13.13.1 Novartis AG Company Information 13.13.2 Novartis AG Osteoporosis Biosimilars Product Portfolios and Specifications 13.13.3 Novartis AG Osteoporosis Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026) 13.13.4 Novartis AG Main Business Overview 13.13.5 Novartis AG Latest Developments 13.14 Cipla Ltd 13.14.1 Cipla Ltd Company Information 13.14.2 Cipla Ltd Osteoporosis Biosimilars Product Portfolios and Specifications 13.14.3 Cipla Ltd Osteoporosis Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026) 13.14.4 Cipla Ltd Main Business Overview 13.14.5 Cipla Ltd Latest Developments 13.15 CrownBio Science (Jilin) Co., Ltd 13.15.1 CrownBio Science (Jilin) Co., Ltd Company Information 13.15.2 CrownBio Science (Jilin) Co., Ltd Osteoporosis Biosimilars Product Portfolios and Specifications 13.15.3 CrownBio Science (Jilin) Co., Ltd Osteoporosis Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026) 13.15.4 CrownBio Science (Jilin) Co., Ltd Main Business Overview 13.15.5 CrownBio Science (Jilin) Co., Ltd Latest Developments 13.16 LianKang Biotechnology Group 13.16.1 LianKang Biotechnology Group Company Information 13.16.2 LianKang Biotechnology Group Osteoporosis Biosimilars Product Portfolios and Specifications 13.16.3 LianKang Biotechnology Group Osteoporosis Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026) 13.16.4 LianKang Biotechnology Group Main Business Overview 13.16.5 LianKang Biotechnology Group Latest Developments 13.17 Shanghai United Cell Bioengineering Co., Ltd 13.17.1 Shanghai United Cell Bioengineering Co., Ltd Company Information 13.17.2 Shanghai United Cell Bioengineering Co., Ltd Osteoporosis Biosimilars Product Portfolios and Specifications 13.17.3 Shanghai United Cell Bioengineering Co., Ltd Osteoporosis Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026) 13.17.4 Shanghai United Cell Bioengineering Co., Ltd Main Business Overview 13.17.5 Shanghai United Cell Bioengineering Co., Ltd Latest Developments 13.18 Shenzhen Salubris Pharmaceuticals Co., Ltd 13.18.1 Shenzhen Salubris Pharmaceuticals Co., Ltd Company Information 13.18.2 Shenzhen Salubris Pharmaceuticals Co., Ltd Osteoporosis Biosimilars Product Portfolios and Specifications 13.18.3 Shenzhen Salubris Pharmaceuticals Co., Ltd Osteoporosis Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026) 13.18.4 Shenzhen Salubris Pharmaceuticals Co., Ltd Main Business Overview 13.18.5 Shenzhen Salubris Pharmaceuticals Co., Ltd Latest Developments 13.19 Shandong Boyan Biotechnology Co., Ltd 13.19.1 Shandong Boyan Biotechnology Co., Ltd Company Information 13.19.2 Shandong Boyan Biotechnology Co., Ltd Osteoporosis Biosimilars Product Portfolios and Specifications 13.19.3 Shandong Boyan Biotechnology Co., Ltd Osteoporosis Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026) 13.19.4 Shandong Boyan Biotechnology Co., Ltd Main Business Overview 13.19.5 Shandong Boyan Biotechnology Co., Ltd Latest Developments 13.20 Mabwell (Shanghai) Biotechnology 13.20.1 Mabwell (Shanghai) Biotechnology Company Information 13.20.2 Mabwell (Shanghai) Biotechnology Osteoporosis Biosimilars Product Portfolios and Specifications 13.20.3 Mabwell (Shanghai) Biotechnology Osteoporosis Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026) 13.20.4 Mabwell (Shanghai) Biotechnology Main Business Overview 13.20.5 Mabwell (Shanghai) Biotechnology Latest Developments 13.21 Qilu Pharmaceutical Co., Ltd 13.21.1 Qilu Pharmaceutical Co., Ltd Company Information 13.21.2 Qilu Pharmaceutical Co., Ltd Osteoporosis Biosimilars Product Portfolios and Specifications 13.21.3 Qilu Pharmaceutical Co., Ltd Osteoporosis Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026) 13.21.4 Qilu Pharmaceutical Co., Ltd Main Business Overview 13.21.5 Qilu Pharmaceutical Co., Ltd Latest Developments 14 Research Findings and Conclusion List of Tables/GraphsList of TablesTable 1. Osteoporosis Biosimilars Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions) Table 2. Osteoporosis Biosimilars Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions) Table 3. Major Players of 250μg/mL Table 4. Major Players of 60 mg/mL Table 5. Major Players of 70 mg/mL Table 6. Global Osteoporosis Biosimilars Sales by Type (2021-2026) & (K Units) Table 7. Global Osteoporosis Biosimilars Sales Market Share by Type (2021-2026) Table 8. Global Osteoporosis Biosimilars Revenue by Type (2021-2026) & ($ million) Table 9. Global Osteoporosis Biosimilars Revenue Market Share by Type (2021-2026) Table 10. Global Osteoporosis Biosimilars Sale Price by Type (2021-2026) & (US$/Unit) Table 11. Global Osteoporosis Biosimilars Sale by Application (2021-2026) & (K Units) Table 12. Global Osteoporosis Biosimilars Sale Market Share by Application (2021-2026) Table 13. Global Osteoporosis Biosimilars Revenue by Application (2021-2026) & ($ million) Table 14. Global Osteoporosis Biosimilars Revenue Market Share by Application (2021-2026) Table 15. Global Osteoporosis Biosimilars Sale Price by Application (2021-2026) & (US$/Unit) Table 16. Global Osteoporosis Biosimilars Sales by Company (2021-2026) & (K Units) Table 17. Global Osteoporosis Biosimilars Sales Market Share by Company (2021-2026) Table 18. Global Osteoporosis Biosimilars Revenue by Company (2021-2026) & ($ millions) Table 19. Global Osteoporosis Biosimilars Revenue Market Share by Company (2021-2026) Table 20. Global Osteoporosis Biosimilars Sale Price by Company (2021-2026) & (US$/Unit) Table 21. Key Manufacturers Osteoporosis Biosimilars Producing Area Distribution and Sales Area Table 22. Players Osteoporosis Biosimilars Products Offered Table 23. Osteoporosis Biosimilars Concentration Ratio (CR3, CR5 and CR10) & (2024-2026) Table 24. New Products and Potential Entrants Table 25. Market M&A Activity & Strategy Table 26. Global Osteoporosis Biosimilars Sales by Geographic Region (2021-2026) & (K Units) Table 27. Global Osteoporosis Biosimilars Sales Market Share Geographic Region (2021-2026) Table 28. Global Osteoporosis Biosimilars Revenue by Geographic Region (2021-2026) & ($ millions) Table 29. Global Osteoporosis Biosimilars Revenue Market Share by Geographic Region (2021-2026) Table 30. Global Osteoporosis Biosimilars Sales by Country/Region (2021-2026) & (K Units) Table 31. Global Osteoporosis Biosimilars Sales Market Share by Country/Region (2021-2026) Table 32. Global Osteoporosis Biosimilars Revenue by Country/Region (2021-2026) & ($ millions) Table 33. Global Osteoporosis Biosimilars Revenue Market Share by Country/Region (2021-2026) Table 34. Americas Osteoporosis Biosimilars Sales by Country (2021-2026) & (K Units) Table 35. Americas Osteoporosis Biosimilars Sales Market Share by Country (2021-2026) Table 36. Americas Osteoporosis Biosimilars Revenue by Country (2021-2026) & ($ millions) Table 37. Americas Osteoporosis Biosimilars Sales by Type (2021-2026) & (K Units) Table 38. Americas Osteoporosis Biosimilars Sales by Application (2021-2026) & (K Units) Table 39. APAC Osteoporosis Biosimilars Sales by Region (2021-2026) & (K Units) Table 40. APAC Osteoporosis Biosimilars Sales Market Share by Region (2021-2026) Table 41. APAC Osteoporosis Biosimilars Revenue by Region (2021-2026) & ($ millions) Table 42. APAC Osteoporosis Biosimilars Sales by Type (2021-2026) & (K Units) Table 43. APAC Osteoporosis Biosimilars Sales by Application (2021-2026) & (K Units) Table 44. Europe Osteoporosis Biosimilars Sales by Country (2021-2026) & (K Units) Table 45. Europe Osteoporosis Biosimilars Revenue by Country (2021-2026) & ($ millions) Table 46. Europe Osteoporosis Biosimilars Sales by Type (2021-2026) & (K Units) Table 47. Europe Osteoporosis Biosimilars Sales by Application (2021-2026) & (K Units) Table 48. Middle East & Africa Osteoporosis Biosimilars Sales by Country (2021-2026) & (K Units) Table 49. Middle East & Africa Osteoporosis Biosimilars Revenue Market Share by Country (2021-2026) Table 50. Middle East & Africa Osteoporosis Biosimilars Sales by Type (2021-2026) & (K Units) Table 51. Middle East & Africa Osteoporosis Biosimilars Sales by Application (2021-2026) & (K Units) Table 52. Key Market Drivers & Growth Opportunities of Osteoporosis Biosimilars Table 53. Key Market Challenges & Risks of Osteoporosis Biosimilars Table 54. Key Industry Trends of Osteoporosis Biosimilars Table 55. Osteoporosis Biosimilars Raw Material Table 56. Key Suppliers of Raw Materials Table 57. Osteoporosis Biosimilars Distributors List Table 58. Osteoporosis Biosimilars Customer List Table 59. Global Osteoporosis Biosimilars Sales Forecast by Region (2027-2032) & (K Units) Table 60. Global Osteoporosis Biosimilars Revenue Forecast by Region (2027-2032) & ($ millions) Table 61. Americas Osteoporosis Biosimilars Sales Forecast by Country (2027-2032) & (K Units) Table 62. Americas Osteoporosis Biosimilars Annual Revenue Forecast by Country (2027-2032) & ($ millions) Table 63. APAC Osteoporosis Biosimilars Sales Forecast by Region (2027-2032) & (K Units) Table 64. APAC Osteoporosis Biosimilars Annual Revenue Forecast by Region (2027-2032) & ($ millions) Table 65. Europe Osteoporosis Biosimilars Sales Forecast by Country (2027-2032) & (K Units) Table 66. Europe Osteoporosis Biosimilars Revenue Forecast by Country (2027-2032) & ($ millions) Table 67. Middle East & Africa Osteoporosis Biosimilars Sales Forecast by Country (2027-2032) & (K Units) Table 68. Middle East & Africa Osteoporosis Biosimilars Revenue Forecast by Country (2027-2032) & ($ millions) Table 69. Global Osteoporosis Biosimilars Sales Forecast by Type (2027-2032) & (K Units) Table 70. Global Osteoporosis Biosimilars Revenue Forecast by Type (2027-2032) & ($ millions) Table 71. Global Osteoporosis Biosimilars Sales Forecast by Application (2027-2032) & (K Units) Table 72. Global Osteoporosis Biosimilars Revenue Forecast by Application (2027-2032) & ($ millions) Table 73. Biosidus SA Basic Information, Osteoporosis Biosimilars Manufacturing Base, Sales Area and Its Competitors Table 74. Biosidus SA Osteoporosis Biosimilars Product Portfolios and Specifications Table 75. Biosidus SA Osteoporosis Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Biosidus SA Main Business Table 77. Biosidus SA Latest Developments Table 78. Cadila Pharmaceuticals Basic Information, Osteoporosis Biosimilars Manufacturing Base, Sales Area and Its Competitors Table 79. Cadila Pharmaceuticals Osteoporosis Biosimilars Product Portfolios and Specifications Table 80. Cadila Pharmaceuticals Osteoporosis Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Cadila Pharmaceuticals Main Business Table 82. Cadila Pharmaceuticals Latest Developments Table 83. Gedeon Richter Australia Pty Ltd Basic Information, Osteoporosis Biosimilars Manufacturing Base, Sales Area and Its Competitors Table 84. Gedeon Richter Australia Pty Ltd Osteoporosis Biosimilars Product Portfolios and Specifications Table 85. Gedeon Richter Australia Pty Ltd Osteoporosis Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Gedeon Richter Australia Pty Ltd Main Business Table 87. Gedeon Richter Australia Pty Ltd Latest Developments Table 88. Mochida Pharmaceutical Co., Ltd Basic Information, Osteoporosis Biosimilars Manufacturing Base, Sales Area and Its Competitors Table 89. Mochida Pharmaceutical Co., Ltd Osteoporosis Biosimilars Product Portfolios and Specifications Table 90. Mochida Pharmaceutical Co., Ltd Osteoporosis Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Mochida Pharmaceutical Co., Ltd Main Business Table 92. Mochida Pharmaceutical Co., Ltd Latest Developments Table 93. STADA Arzneimittel AG Basic Information, Osteoporosis Biosimilars Manufacturing Base, Sales Area and Its Competitors Table 94. STADA Arzneimittel AG Osteoporosis Biosimilars Product Portfolios and Specifications Table 95. STADA Arzneimittel AG Osteoporosis Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. STADA Arzneimittel AG Main Business Table 97. STADA Arzneimittel AG Latest Developments Table 98. Alvogen, Inc Basic Information, Osteoporosis Biosimilars Manufacturing Base, Sales Area and Its Competitors Table 99. Alvogen, Inc Osteoporosis Biosimilars Product Portfolios and Specifications Table 100. Alvogen, Inc Osteoporosis Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Alvogen, Inc Main Business Table 102. Alvogen, Inc Latest Developments Table 103. Theramex Ireland Ltd Basic Information, Osteoporosis Biosimilars Manufacturing Base, Sales Area and Its Competitors Table 104. Theramex Ireland Ltd Osteoporosis Biosimilars Product Portfolios and Specifications Table 105. Theramex Ireland Ltd Osteoporosis Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Theramex Ireland Ltd Main Business Table 107. Theramex Ireland Ltd Latest Developments Table 108. Intas Pharmaceuticals Ltd Basic Information, Osteoporosis Biosimilars Manufacturing Base, Sales Area and Its Competitors Table 109. Intas Pharmaceuticals Ltd Osteoporosis Biosimilars Product Portfolios and Specifications Table 110. Intas Pharmaceuticals Ltd Osteoporosis Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Intas Pharmaceuticals Ltd Main Business Table 112. Intas Pharmaceuticals Ltd Latest Developments Table 113. Sun Pharma ANZ Pty Ltd Basic Information, Osteoporosis Biosimilars Manufacturing Base, Sales Area and Its Competitors Table 114. Sun Pharma ANZ Pty Ltd Osteoporosis Biosimilars Product Portfolios and Specifications Table 115. Sun Pharma ANZ Pty Ltd Osteoporosis Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Sun Pharma ANZ Pty Ltd Main Business Table 117. Sun Pharma ANZ Pty Ltd Latest Developments Table 118. Strides Pharma Basic Information, Osteoporosis Biosimilars Manufacturing Base, Sales Area and Its Competitors Table 119. Strides Pharma Osteoporosis Biosimilars Product Portfolios and Specifications Table 120. Strides Pharma Osteoporosis Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Strides Pharma Main Business Table 122. Strides Pharma Latest Developments Table 123. Apotex Corp Basic Information, Osteoporosis Biosimilars Manufacturing Base, Sales Area and Its Competitors Table 124. Apotex Corp Osteoporosis Biosimilars Product Portfolios and Specifications Table 125. Apotex Corp Osteoporosis Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Apotex Corp Main Business Table 127. Apotex Corp Latest Developments Table 128. Teva Pharmaceuticals, Inc Basic Information, Osteoporosis Biosimilars Manufacturing Base, Sales Area and Its Competitors Table 129. Teva Pharmaceuticals, Inc Osteoporosis Biosimilars Product Portfolios and Specifications Table 130. Teva Pharmaceuticals, Inc Osteoporosis Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. Teva Pharmaceuticals, Inc Main Business Table 132. Teva Pharmaceuticals, Inc Latest Developments Table 133. Novartis AG Basic Information, Osteoporosis Biosimilars Manufacturing Base, Sales Area and Its Competitors Table 134. Novartis AG Osteoporosis Biosimilars Product Portfolios and Specifications Table 135. Novartis AG Osteoporosis Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. Novartis AG Main Business Table 137. Novartis AG Latest Developments Table 138. Cipla Ltd Basic Information, Osteoporosis Biosimilars Manufacturing Base, Sales Area and Its Competitors Table 139. Cipla Ltd Osteoporosis Biosimilars Product Portfolios and Specifications Table 140. Cipla Ltd Osteoporosis Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 141. Cipla Ltd Main Business Table 142. Cipla Ltd Latest Developments Table 143. CrownBio Science (Jilin) Co., Ltd Basic Information, Osteoporosis Biosimilars Manufacturing Base, Sales Area and Its Competitors Table 144. CrownBio Science (Jilin) Co., Ltd Osteoporosis Biosimilars Product Portfolios and Specifications Table 145. CrownBio Science (Jilin) Co., Ltd Osteoporosis Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 146. CrownBio Science (Jilin) Co., Ltd Main Business Table 147. CrownBio Science (Jilin) Co., Ltd Latest Developments Table 148. LianKang Biotechnology Group Basic Information, Osteoporosis Biosimilars Manufacturing Base, Sales Area and Its Competitors Table 149. LianKang Biotechnology Group Osteoporosis Biosimilars Product Portfolios and Specifications Table 150. LianKang Biotechnology Group Osteoporosis Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 151. LianKang Biotechnology Group Main Business Table 152. LianKang Biotechnology Group Latest Developments Table 153. Shanghai United Cell Bioengineering Co., Ltd Basic Information, Osteoporosis Biosimilars Manufacturing Base, Sales Area and Its Competitors Table 154. Shanghai United Cell Bioengineering Co., Ltd Osteoporosis Biosimilars Product Portfolios and Specifications Table 155. Shanghai United Cell Bioengineering Co., Ltd Osteoporosis Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 156. Shanghai United Cell Bioengineering Co., Ltd Main Business Table 157. Shanghai United Cell Bioengineering Co., Ltd Latest Developments Table 158. Shenzhen Salubris Pharmaceuticals Co., Ltd Basic Information, Osteoporosis Biosimilars Manufacturing Base, Sales Area and Its Competitors Table 159. Shenzhen Salubris Pharmaceuticals Co., Ltd Osteoporosis Biosimilars Product Portfolios and Specifications Table 160. Shenzhen Salubris Pharmaceuticals Co., Ltd Osteoporosis Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 161. Shenzhen Salubris Pharmaceuticals Co., Ltd Main Business Table 162. Shenzhen Salubris Pharmaceuticals Co., Ltd Latest Developments Table 163. Shandong Boyan Biotechnology Co., Ltd Basic Information, Osteoporosis Biosimilars Manufacturing Base, Sales Area and Its Competitors Table 164. Shandong Boyan Biotechnology Co., Ltd Osteoporosis Biosimilars Product Portfolios and Specifications Table 165. Shandong Boyan Biotechnology Co., Ltd Osteoporosis Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 166. Shandong Boyan Biotechnology Co., Ltd Main Business Table 167. Shandong Boyan Biotechnology Co., Ltd Latest Developments Table 168. Mabwell (Shanghai) Biotechnology Basic Information, Osteoporosis Biosimilars Manufacturing Base, Sales Area and Its Competitors Table 169. Mabwell (Shanghai) Biotechnology Osteoporosis Biosimilars Product Portfolios and Specifications Table 170. Mabwell (Shanghai) Biotechnology Osteoporosis Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 171. Mabwell (Shanghai) Biotechnology Main Business Table 172. Mabwell (Shanghai) Biotechnology Latest Developments Table 173. Qilu Pharmaceutical Co., Ltd Basic Information, Osteoporosis Biosimilars Manufacturing Base, Sales Area and Its Competitors Table 174. Qilu Pharmaceutical Co., Ltd Osteoporosis Biosimilars Product Portfolios and Specifications Table 175. Qilu Pharmaceutical Co., Ltd Osteoporosis Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 176. Qilu Pharmaceutical Co., Ltd Main Business Table 177. Qilu Pharmaceutical Co., Ltd Latest Developments List of Figures Figure 1. Picture of Osteoporosis Biosimilars Figure 2. Osteoporosis Biosimilars Report Years Considered Figure 3. Research Objectives Figure 4. Research Methodology Figure 5. Research Process and Data Source Figure 6. Global Osteoporosis Biosimilars Sales Growth Rate 2021-2032 (K Units) Figure 7. Global Osteoporosis Biosimilars Revenue Growth Rate 2021-2032 ($ millions) Figure 8. Osteoporosis Biosimilars Sales by Geographic Region (2021, 2025 & 2032) & ($ millions) Figure 9. Osteoporosis Biosimilars Sales Market Share by Country/Region (2025) Figure 10. Osteoporosis Biosimilars Sales Market Share by Country/Region (2021, 2025 & 2032) Figure 11. Product Picture of 250μg/mL Figure 12. Product Picture of 60 mg/mL Figure 13. Product Picture of 70 mg/mL Figure 14. Global Osteoporosis Biosimilars Sales Market Share by Type in 2026 Figure 15. Global Osteoporosis Biosimilars Revenue Market Share by Type (2021-2026) Figure 16. Osteoporosis Biosimilars Consumed in Hospital Figure 17. Global Osteoporosis Biosimilars Market: Hospital (2021-2026) & (K Units) Figure 18. Osteoporosis Biosimilars Consumed in Clinic Figure 19. Global Osteoporosis Biosimilars Market: Clinic (2021-2026) & (K Units) Figure 20. Osteoporosis Biosimilars Consumed in Others Figure 21. Global Osteoporosis Biosimilars Market: Others (2021-2026) & (K Units) Figure 22. Global Osteoporosis Biosimilars Sale Market Share by Application (2025) Figure 23. Global Osteoporosis Biosimilars Revenue Market Share by Application in 2026 Figure 24. Osteoporosis Biosimilars Sales by Company in 2026 (K Units) Figure 25. Global Osteoporosis Biosimilars Sales Market Share by Company in 2026 Figure 26. Osteoporosis Biosimilars Revenue by Company in 2026 ($ millions) Figure 27. Global Osteoporosis Biosimilars Revenue Market Share by Company in 2026 Figure 28. Global Osteoporosis Biosimilars Sales Market Share by Geographic Region (2021-2026) Figure 29. Global Osteoporosis Biosimilars Revenue Market Share by Geographic Region in 2026 Figure 30. Americas Osteoporosis Biosimilars Sales 2021-2026 (K Units) Figure 31. Americas Osteoporosis Biosimilars Revenue 2021-2026 ($ millions) Figure 32. APAC Osteoporosis Biosimilars Sales 2021-2026 (K Units) Figure 33. APAC Osteoporosis Biosimilars Revenue 2021-2026 ($ millions) Figure 34. Europe Osteoporosis Biosimilars Sales 2021-2026 (K Units) Figure 35. Europe Osteoporosis Biosimilars Revenue 2021-2026 ($ millions) Figure 36. Middle East & Africa Osteoporosis Biosimilars Sales 2021-2026 (K Units) Figure 37. Middle East & Africa Osteoporosis Biosimilars Revenue 2021-2026 ($ millions) Figure 38. Americas Osteoporosis Biosimilars Sales Market Share by Country in 2026 Figure 39. Americas Osteoporosis Biosimilars Revenue Market Share by Country (2021-2026) Figure 40. Americas Osteoporosis Biosimilars Sales Market Share by Type (2021-2026) Figure 41. Americas Osteoporosis Biosimilars Sales Market Share by Application (2021-2026) Figure 42. United States Osteoporosis Biosimilars Revenue Growth 2021-2026 ($ millions) Figure 43. Canada Osteoporosis Biosimilars Revenue Growth 2021-2026 ($ millions) Figure 44. Mexico Osteoporosis Biosimilars Revenue Growth 2021-2026 ($ millions) Figure 45. Brazil Osteoporosis Biosimilars Revenue Growth 2021-2026 ($ millions) Figure 46. APAC Osteoporosis Biosimilars Sales Market Share by Region in 2026 Figure 47. APAC Osteoporosis Biosimilars Revenue Market Share by Region (2021-2026) Figure 48. APAC Osteoporosis Biosimilars Sales Market Share by Type (2021-2026) Figure 49. APAC Osteoporosis Biosimilars Sales Market Share by Application (2021-2026) Figure 50. China Osteoporosis Biosimilars Revenue Growth 2021-2026 ($ millions) Figure 51. Japan Osteoporosis Biosimilars Revenue Growth 2021-2026 ($ millions) Figure 52. South Korea Osteoporosis Biosimilars Revenue Growth 2021-2026 ($ millions) Figure 53. Southeast Asia Osteoporosis Biosimilars Revenue Growth 2021-2026 ($ millions) Figure 54. India Osteoporosis Biosimilars Revenue Growth 2021-2026 ($ millions) Figure 55. Australia Osteoporosis Biosimilars Revenue Growth 2021-2026 ($ millions) Figure 56. China Taiwan Osteoporosis Biosimilars Revenue Growth 2021-2026 ($ millions) Figure 57. Europe Osteoporosis Biosimilars Sales Market Share by Country in 2026 Figure 58. Europe Osteoporosis Biosimilars Revenue Market Share by Country (2021-2026) Figure 59. Europe Osteoporosis Biosimilars Sales Market Share by Type (2021-2026) Figure 60. Europe Osteoporosis Biosimilars Sales Market Share by Application (2021-2026) Figure 61. Germany Osteoporosis Biosimilars Revenue Growth 2021-2026 ($ millions) Figure 62. France Osteoporosis Biosimilars Revenue Growth 2021-2026 ($ millions) Figure 63. UK Osteoporosis Biosimilars Revenue Growth 2021-2026 ($ millions) Figure 64. Italy Osteoporosis Biosimilars Revenue Growth 2021-2026 ($ millions) Figure 65. Russia Osteoporosis Biosimilars Revenue Growth 2021-2026 ($ millions) Figure 66. Middle East & Africa Osteoporosis Biosimilars Sales Market Share by Country (2021-2026) Figure 67. Middle East & Africa Osteoporosis Biosimilars Sales Market Share by Type (2021-2026) Figure 68. Middle East & Africa Osteoporosis Biosimilars Sales Market Share by Application (2021-2026) Figure 69. Egypt Osteoporosis Biosimilars Revenue Growth 2021-2026 ($ millions) Figure 70. South Africa Osteoporosis Biosimilars Revenue Growth 2021-2026 ($ millions) Figure 71. Israel Osteoporosis Biosimilars Revenue Growth 2021-2026 ($ millions) Figure 72. Turkey Osteoporosis Biosimilars Revenue Growth 2021-2026 ($ millions) Figure 73. GCC Countries Osteoporosis Biosimilars Revenue Growth 2021-2026 ($ millions) Figure 74. Manufacturing Cost Structure Analysis of Osteoporosis Biosimilars in 2026 Figure 75. Manufacturing Process Analysis of Osteoporosis Biosimilars Figure 76. Industry Chain Structure of Osteoporosis Biosimilars Figure 77. Channels of Distribution Figure 78. Global Osteoporosis Biosimilars Sales Market Forecast by Region (2027-2032) Figure 79. Global Osteoporosis Biosimilars Revenue Market Share Forecast by Region (2027-2032) Figure 80. Global Osteoporosis Biosimilars Sales Market Share Forecast by Type (2027-2032) Figure 81. Global Osteoporosis Biosimilars Revenue Market Share Forecast by Type (2027-2032) Figure 82. Global Osteoporosis Biosimilars Sales Market Share Forecast by Application (2027-2032) Figure 83. Global Osteoporosis Biosimilars Revenue Market Share Forecast by Application (2027-2032)
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医薬）の最新刊レポート
LP Information社の 医薬品・ヘルスケア分野 での最新刊レポート
本レポートと同じKEY WORD（biosimilars）の最新刊レポート
よくあるご質問LP Information社はどのような調査会社ですか?LP Informationは通信、エネルギー、医薬をはじめとする広範な市場の調査とレポート出版を行っている調査会社です。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
|
